3
|
Fang Y, Yuan Z, Zhang H, Wang P, Hao J. Predictive Value of Serum Heat Shock Protein 90α on the Prognosis of Patients with Lung Adenocarcinoma. J Inflamm Res 2023; 16:1183-1193. [PMID: 36960296 PMCID: PMC10028300 DOI: 10.2147/jir.s401444] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 02/22/2023] [Indexed: 03/18/2023] Open
Abstract
Purpose Heat shock protein 90α (HSP90α) is highly expressed in tumors, and predicts tumor progression. This study analyzed the correlation between the expression level of HSP90α in the serum and the prognosis of patients with lung adenocarcinoma. Patients and methods The medical records of patients with 228 lung adenocarcinoma from September 2015 to December 2021 were analyzed. HSP90α expression in the patients' serum was detected by ELISA and the cut-off value (93.76 ng/mL) was determined according to the ROC curve, then the patients were divided into high- and low-level groups. The differences in the medical records of the two groups were compared using the X2 test, and Univariate and multivariate Cox regression analyses showed that serum HSP90α level were independent risk factors for both PFS and OS (P < 0.05). Results HSP90α was positively correlated with TNM staging (P < 0.01) by One-way analysis of variance. The results of the correlation analysis and the Kaplan-Meier survival curve showed that the expression levels of HSP90α and CEA of patients were positively correlated (R=0.54, P < 0.001), and patients with high HSP90α and CEA levels had the worst OS (P < 0.001). Conclusion HSP90α expression is negatively correlated with the prognosis of patients with lung adenocarcinoma and is a potential prognostic marker.
Collapse
Affiliation(s)
- Yue Fang
- Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China
- Intern of Oncology, Hefei Cancer Hospital, Chinese Academy of Sciences (CAS), Hefei, People’s Republic of China
| | - Zhichao Yuan
- Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China
| | - Hao Zhang
- Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China
| | - Peng Wang
- Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China
| | - Jiqing Hao
- Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China
- Correspondence: Jiqing Hao, Email
| |
Collapse
|
5
|
Su K, Liu Y, Wang P, He K, Wang F, Chi H, Rao M, Li X, Wen L, Song Y, Zhang J, Gu T, Xu K, Li Q, Chen J, Wu Z, Li H, Huang W, Chen L, Tong J, Li H, Feng X, Chen S, Yang B, Jin H, Yang Y, Liu H, Yang C, Wu M, Xiong F, Peng K, Zhu L, Xu Y, Tang X, Tan Z, Luo X, Zheng H, Zhang Y, Guo L, Han Y. Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study. Hepatol Int 2022; 16:1208-1219. [PMID: 35972640 PMCID: PMC9525341 DOI: 10.1007/s12072-022-10391-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2022] [Accepted: 07/09/2022] [Indexed: 01/10/2023]
Abstract
BACKGROUND Although the diagnostic value of plasma heat-shock protein 90α (HSP90α) in hepatocellular carcinoma (HCC) has been previously reported, the causal effect of the plasma HSP90α levels on HCC prognosis remains largely unclear. To this extent, we sought to assess whether the plasma HSP90α acts as a prognostic factor for HCC patients. METHODS A total of 2150 HCC patients were included in this retrospective study between August 2016 and July 2021. Plasma HSP90α levels were tested within a week before treatment and their association with prognosis was assessed. RESULTS An optimal cutoff value of 143.5 for the HSP90α based on the overall survival (OS) was determined using the X-tile software. HCC patients with HSP90α < 143.5 ng/mL (low HSP90α) before and after propensity score matching (PSM) indicated longer median OS (mOS) relative to those with HSP90α ≥ 143.5 ng/mL (high HSP90α) (37.0 vs. 9.0 months, p < 0.001; 19.2 vs. 9.6 months, p < 0.001; respectively). In addition, the high HSP90α plasma level is an independent poor prognostic factor for OS in HCC patients. In our subgroup analysis, including the supportive care group, surgery group, transarterial chemoembolization (TACE) group, adjuvant TACE group, an immune checkpoint inhibitor (ICI) plus targeted therapy group, and TACE plus ICI group, the high HSP90α group demonstrated better OS compared to the low HSP90α group. Moreover, in the supportive care, TACE, ICI plus targeted therapy, TACE plus ICI groups, and high HSP90α levels were also an independent poor prognostic factors for OS. CONCLUSIONS Our study confirmed that the plasma HSP90α level can be used as a prognostic biomarker for HCC.
Collapse
Affiliation(s)
- Ke Su
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Yanlin Liu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Pan Wang
- Clinical Skills Center, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China
| | - Kun He
- Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China
| | - Fei Wang
- Department of General Surgery, Luxian People's Hospital, Luzhou, 646199, China
| | - Hao Chi
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Mingyue Rao
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Xueting Li
- Department of Oncology, 363 Hospital, Chengdu, 610041, China
| | - Lianbin Wen
- Department of Geriatric Cardiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, 610072, China
| | - Yanqiong Song
- Department of Radiotherapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610042, China
| | - Jianwen Zhang
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Tao Gu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Ke Xu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Qi Li
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Jiali Chen
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Zhenying Wu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Han Li
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China
| | - Weihong Huang
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Lan Chen
- Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China
| | - Jian Tong
- Department of Spinal Surgery, No.1 Orthopedics Hospital of Chengdu, Chengdu, 610000, China
| | - Hongyan Li
- Department of Anesthesiology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China
| | - Xunjie Feng
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Siyu Chen
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Binbin Yang
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Hongping Jin
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Yue Yang
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Hanlin Liu
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Chao Yang
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Ming Wu
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Fangyu Xiong
- Department of Medical Inspection Technology, Southwest Medical University, Luzhou, 646000, China
| | - Keyi Peng
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Lechuan Zhu
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Yaoyang Xu
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Xue Tang
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Zunyuan Tan
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Xiaotong Luo
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Hanyue Zheng
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Yuxin Zhang
- Clinical Medical College, Southwest Medical University, Luzhou, 646000, China
| | - Lu Guo
- Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 646000, Sichuan, China.
| | - Yunwei Han
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, 646000, China.
- Academician (Expert) Workstation of Sichuan Province, Luzhou, 646000, China.
| |
Collapse
|
6
|
Yuan Z, Wang L, Chen C. Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors. Front Oncol 2022; 12:963719. [PMID: 36158677 PMCID: PMC9499179 DOI: 10.3389/fonc.2022.963719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 08/19/2022] [Indexed: 11/13/2022] Open
Abstract
Heat shock protein 90α (HSP90α) encoded by the HSP90AA1 gene, is the stress inducible isoform of the molecular chaperone HSP90, and was demonstrated as a promising hallmark to diagnose, prognosis in malignant tumors. This study is to evaluate the value of HSP90α in diagnosis, prognosis and immunotherapy of malignant tumors by investigating the expression of HSP90α in plasma of various tumors and analyzing the expression of HSP90α at gene and protein levels via pan-cancer database. We founded that levels of HSP90α in malignant tumors groups were significantly higher than healthy controls in serum. Pan-cancer analysis showed that HSP90AA1 was highly expressed in 27 of 33 tumors, but low in individual cancers (such as renal malignancies). The plasma HSP90α level was positively correlated with the stage of malignant tumor, but there was no significant difference between HSP90AA1 and the stage of most tumors. Cox regression analysis showed that HSP90AA1 expression was significantly correlated with OS in only 6 of the 32 cancers, including LIHC, KIRC, HNSC, LUAD, BRCA and MESO. Up-regulation of HSP90AA1 in most tumors was positively correlated with PDCD1LG2 and CD274 immune checkpoint genes. T cell CD8+ was positively correlated with HSP90AA1 in COAD, DLBC and UVM, and negatively correlated with HSP90AA1 in ESCA, GBM, HNSC, KIRC, KIRP, UCEC and STAD. The AUC of HSP90α are generally high in different tumor groups, which indicated its diagnostic value in malignant tumors. In conclusion, serum HSP90α in patients with malignant tumor is generally elevated, which is of positive significance as an independent diagnosis and combined diagnosis. However, we found that the expression level of HSP90AA1 gene in most tumors was not completely consistent with the serum level, and even down-regulated in some tumors. Plasma levels can be used as biomarkers of poor prognosis in some tumors, but it cannot be used as a biomarker for poor prognosis of all tumors, and more in-depth studies are needed.
Collapse
Affiliation(s)
- Zhimin Yuan
- Xi’an Jiaotong University, Xi’an, China
- Department of Clinical Laboratory, Shaanxi Provincial Cancer Hospital, Xi’an, China
| | - Longhao Wang
- Department of Otorhinolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Cheng Chen
- Department of General Dentistry/Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi’an Jiaotong University, Xi’an, China
- *Correspondence: Cheng Chen,
| |
Collapse
|